Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab (TAKHZYRO) in Chinese Subjects with Hereditary Angioedema
2023-001105-31Phase 3
- Sponsor
- Takeda
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2023-001105-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001105-31.